169 related articles for article (PubMed ID: 38518192)
1. Development of small molecule drugs targeting immune checkpoints.
Chen L; Zhao X; Liu X; Ouyang Y; Xu C; Shi Y
Cancer Biol Med; 2024 May; 21(5):382-99. PubMed ID: 38727005
[TBL] [Abstract][Full Text] [Related]
2. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.
Pitts SC; Schlom J; Donahue RN
J Exp Clin Cancer Res; 2024 May; 43(1):155. PubMed ID: 38822401
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoints in Endometriosis-A New Insight in the Pathogenesis.
Suszczyk D; Skiba W; Pawłowska-Łachut A; Dymanowska-Dyjak I; Włodarczyk K; Paduch R; Wertel I
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892453
[TBL] [Abstract][Full Text] [Related]
4. Extracellular vesicles mediated gastric cancer immune response: tumor cell death or immune escape?
Yang S; Wei S; Wei F
Cell Death Dis; 2024 May; 15(5):377. PubMed ID: 38816455
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint molecules in solid organ transplantation: A promising way to prevent rejection.
Righi I; Trabattoni D; Rosso L; Vaira V; Clerici M
Immunol Lett; 2024 Jun; 267():106860. PubMed ID: 38677335
[TBL] [Abstract][Full Text] [Related]
6. Buena VISTA: a promising outlook on targeting immune checkpoint regulators to combat sepsis.
Mott MD; Trusiano B; Allen IC
J Leukoc Biol; 2024 May; 115(6):1002-1004. PubMed ID: 38526166
[No Abstract] [Full Text] [Related]
7. Immune checkpoints between epithelial-mesenchymal transition and autophagy: A conflicting triangle.
Cordani M; Strippoli R; Trionfetti F; Barzegar Behrooz A; Rumio C; Velasco G; Ghavami S; Marcucci F
Cancer Lett; 2024 Mar; 585():216661. PubMed ID: 38309613
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules.
Hazrati A; Malekpour K; Khorramdelazad H; Rajaei S; Hashemi SM
Biomark Res; 2024 Mar; 12(1):35. PubMed ID: 38515166
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract][Full Text] [Related]
10. Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection.
Li W; Syed F; Yu R; Yang J; Xia Y; Relich RF; Russell PM; Zhang S; Khalili M; Huang L; Kacena MA; Zheng X; Yu Q
Front Immunol; 2022; 13():833310. PubMed ID: 35281051
[TBL] [Abstract][Full Text] [Related]
11. The role of extracellular vesicle immune checkpoints in cancer.
Zhang W; Ou M; Yang P; Ning M
Clin Exp Immunol; 2024 May; 216(3):230-239. PubMed ID: 38518192
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.
Srivastava A; Rathore S; Munshi A; Ramesh R
AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060
[TBL] [Abstract][Full Text] [Related]
13. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
14. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicle Heterogeneity and Its Impact for Regenerative Medicine Applications.
van de Wakker SI; Meijers FM; Sluijter JPG; Vader P
Pharmacol Rev; 2023 Sep; 75(5):1043-1061. PubMed ID: 37280097
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
